ACS Publications. Most Trusted. Most Cited. Most Read

OR SEARCH CITATIONS

My Activity
Publications
RETURN TO ISSUEPREVLetterNEXT

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

  • Nadia R. P. W. Hutten
    • , 
  • Natasha L. Mason
    • , 
  • Patrick C. Dolder
    • , 
  • Eef L. Theunissen
    • , 
  • Friederike Holze
    • , 
  • Matthias E. Liechti
    • , 
  • Nimmy Varghese
    • , 
  • Anne Eckert
    • , 
  • Amanda Feilding
    • , 
  • Johannes G. Ramaekers
    • , and 
  • Kim P. C. Kuypers*
Cite this: ACS Pharmacol. Transl. Sci. 2021, 4, 2, 461–466
Publication Date (Web):August 31, 2020
https://doi.org/10.1021/acsptsci.0c00099
Copyright © 2020 American Chemical Society
RIGHTS & PERMISSIONS
ACS AuthorChoiceACS AuthorChoicewith CC-BY-NC-NDlicense
Article Views
19615
Altmetric
195
Citations
16
LEARN ABOUT THESE METRICS
PDF (2 MB)
SUBJECTS:

Abstract

Despite preclinical evidence for psychedelic-induced neuroplasticity, confirmation in humans is grossly lacking. Given the increased interest in using low doses of psychedelics for psychiatric indications and the importance of neuroplasticity in the therapeutic response, this placebo-controlled within-subject study investigated the effect of single low doses of LSD (5, 10, and 20 μg) on circulating BDNF levels in healthy volunteers. Blood samples were collected every 2 h over 6 h, and BDNF levels were determined afterward in blood plasma using ELISA. The findings demonstrated an increase in BDNF blood plasma levels at 4 h (5 μg) and 6 h (5 and 20 μg) compared to that for the placebo. The finding that LSD acutely increases BDNF levels warrants studies in patient populations.

KEYWORDS:

    SPECIAL ISSUE

    This article is part of the Psychedelics special issue.

    Preclinical research has demonstrated that psychedelic substances, including 2,5-dimethoxy-4-iodoamphetamine (DOI), lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and psilocybin, as well as alkaloids present in ayahuasca (harmine, tetrahydroharmine, and harmaline) affect neuroplasticity after acute and chronic administration. (1−5) Catlow and colleagues, for example, demonstrated the increased formation of neurons (neurogenesis) in mice’ dentate gyrus after an average psilocybin dose of 3.5 μg/35 g bodyweight (intraperitoneal (i.p.)), while this was slightly decreased after a dose of 35 μg/35 g (psilocybin/bodyweight). (6) Interestingly, when repeatedly given i.p. psilocybin four times interspersed with 1 week, a higher dose of 52 μg/35 g (psilocybin/bodyweight) increased neuroplasticity. (2) Chronic administration in rats of twice the ritualistic dose of ayahuasca (150 mL/70 kg bodyweight containing 0.26 mg/kg DMT) for 28 days resulted in increased in brain-derived neurotrophic factor (BDNF) levels in the hippocampus of the female rats, compared to that in control animals. (7)
    A recent in vitro study in cultured cortical neurons of animals showed increased formation of new neurites, as expressed by the number of dendritic branches, the total length of the arbors, and formation of synapses, after extended (24 h) treatment with a range of psychedelics like DOI, LSD, and DMT. (1) While these effects were similar across psychedelic classes and the dissociative ketamine, LSD was the most potent, as shown via neuritogenesis assay. (1) Also in cultured human cortical neurons, the neuro-regenerative effects of DMT (8) and modulation of proteins involved in dendritic spine formation by 5-MeO-DMT have been shown. (9)
    In light of the increased scientific interest in using low psychedelic doses, (10) also known as “microdosing”, (11) critical preclinical work with DMT has also shown that neuroplastic changes even take place after administration of low DMT doses that are considered to be subhallucinogenic. (1) Examples are morphological changes in the prefrontal cortex of adult rats and functional changes ex vivo. (1) The practice of microdosing entails repeatedly taking low doses, which are usually one-tenth of a recreational dose that causes a psychedelic experience. For LSD, that would, for example, be between 10 and 20 μg. (12)
    User claims suggest the effectivity of self-medication with low doses of psychedelics in the treatment of disorders related to neuroplasticity, including depression. (10) Interestingly, depression has been linked with impairments in neuroplasticity, and pharmacologically induced symptom improvement is linked with increases in BDNF levels. (13,14) BDNF is highly expressed in limbic brain regions, which are involved in emotional processes, memory, and mood. Notably, Bershad et al. recently demonstrated connectivity changes in the limbic areas after a low dose of LSD (13 μg, tartrate). (15) These biological changes correlated positively with the enhanced mood in healthy volunteers. (15)
    Together, these findings add scientific evidence to the idea that LSD in low doses could have therapeutic potential in mood-related disorders. (10) Given the interest in BDNF as a key player in several neurodegenerative and neuropsychiatric disorders (13,16,17) and preclinical data showing psychedelics-induced neuroplasticity even at low doses of psychedelics, (1) the present double-blind, placebo-controlled, within-subject (WS) study aimed to investigate whether LSD base in low doses (0, 5, 10, and 20 μg) affects BDNF plasma levels in healthy volunteers. Blood samples were collected every 2 h over 6 h, and BDNF levels were determined afterward in blood plasma using ELISA. (18) Previously, it has been demonstrated that blood plasma BDNF concentrations reflect mammalian brain-tissue BDNF levels. (19)

    Results

    ARTICLE SECTIONS
    Jump To
    Difficulties with the peripheral venous catheter during blood sample collection resulted in missing data. For one participant, no blood samples were collected; for the remaining 23 participants, the percentage of samples over all time points ranged from 6 to 100%. Only five (21.7%) of the participants had a complete data set; therefore, we opted to run the analyses per dose for complete cases (placebo–LSD dose) to be able to perform statistical analyses. In Table 1, the demographic details of participants included in the statistical analyses are presented. Four trapezoidal areas under the curves (AUC) for BDNF were calculated for the three LSD doses and placebo; the same procedure was used for LSD concentrations.
    Table 1. Participant Age and Sex per Complete Within-Placebo-LSD Dose Case
    LSD dose (μg)participants (number)mean age (SD)sex (male/female)
    51021.5 (3.06)4:6
    10922.89 (2.80)5:4
    20823.75 (2.66)6:2
    Wilcoxon signed-rank (S-R) tests revealed a statistically significant difference between AUC BDNF levels following 5 ug of LSD (Z = −2.60, p = 0.009, r = 0.58, 95% CI [0.11;1.06]) and 20 μg of LSD (Z = −2.52, p = 0.01, r = 0.63, 95% CI [0.09;1.17]) compared to placebo; the difference between AUC BDNF levels after 10 μg of LSD and placebo was not significant (Z = −1.01, p = 0.31) (Figure 1A). AUC LSD plasma levels for the selection of complete WS cases per dose are shown in Figure 1B for illustrative purposes to show that LSD plasma levels increased with increasing LSD doses.

    Figure 1

    Figure 1. Total mean AUC (SEM) of BDNF (A) and of LSD (B) plasma levels for complete WS LSD dose-placebo cases. N(5 μg LSD) = 10; N(10 μg LSD) = 9; N(20 μg LSD) = 8. *, statistical significance at p ≤ 0.05.

    Wilcoxon S-R tests revealed higher BDNF levels at +4 h after administration of 5 μg of LSD (Z = −2.80, p < 0.01, r = 0.63, 95% CI [0.15; 1.11]) and 10 μg LSD (Z = −1.95, p = 0.05, r = 0.46, 95% CI [−0.04; 0.97]) compared to placebo. Although analysis including the 10 μg dose revealed a statistically significant p value (0.05), the CI included zero, indicating nonsignificance. Tests at +6 h after LSD administration revealed significant effects of 5 μg of LSD (Z = −2.29, p = 0.02, r = 0.51, 95% CI [0.03; 0.99]) and 20 μg of LSD (Z = −2.52, p = 0.01, r = 0.63, 95% CI [0.09; 1.17]) on BDNF levels compared to placebo (Figure 2A–C). Corresponding LSD plasma levels are presented in Figure 2D,E.

    Figure 2

    Figure 2. Mean (SEM) BDNF plasma levels for each LSD dose with the corresponding WS placebo condition per time of testing (A–C) and corresponding mean (SEM) LSD plasma levels (D–F). *, statistical significance at p ≤ 0.05 in A–C; no statistical tests were performed over data in D–F.

    Friedman tests investigating BDNF changes in the function of time demonstrated that BDNF plasma levels remained stable in the placebo conditions throughout the test frame. BDNF plasma levels under the LSD conditions showed their highest levels at 4 h after administration of 5 μg of LSD (8.95 ng/mL), and at 6 h after administration of 10 μg of LSD (8.28 ng/mL) and 20 μg of LSD (11 49 ng/mL) (Table 2).
    Table 2. Friedman Test of Time on BDNF Plasma Levels in the LSD Conditions and Dunn’s Pairwise Comparisons
      Friedman test main time effect Dunn’s pairwise comparisons (Z(1))a
    LSD dose (μg)participants number(x2(3))peffect size Cramer’s V0 h–2 h0 h–4 h0 h–6h2 h–4 h4 h–6 h
    51015.72<0.010.511.213.64*2.77*2.42*0.87
    10913.00<0.010.491.092.56*3.29*1.460.73
    20819.05<0.010.630.772.134.07*1.361.94
    a

    *, statistical significance at a sequential Bonferroni corrected p value < 0.05.

    Discussion

    ARTICLE SECTIONS
    Jump To
    This study provides preliminary evidence that low doses of LSD increase BDNF plasma levels in healthy volunteers up to 6 h after administration, suggesting a window of opportunity for a therapeutic response (20,21) and cognitive enhancement (22,23) that might be of use in patient populations. This line of thinking is supported by recent findings with ketamine and ayahuasca (containing the psychedelic DMT) demonstrating increased serum BDNF levels 24 and 48 h after a single (high) dose, respectively, compared to placebo, which was related to fast antidepressant actions. (21,24,25)
    Of interest is the different time-course of BDNF levels for the 5 μ and 20 μg doses. While BDNF levels peaked at 4 h for the 5 μg dose, these levels significantly increased 2 h later for the 20 μg dose. Recently, Zhang et al. showed that a subanesthetic dose of IV ketamine (10 mg/kg/2h) increased BDNF in the amygdala at 2 h after administration, while 40 mg/kg/2 h did not affect BDNF levels, instead elevating levels of other proteins involved in plasticity (cFos, pERK) in the mPFC and hippocampus. (26) Earlier, they showed that IV ketamine (20 mg/kg/2h) induced a decrease in BDNF plasma in rats at 2 h after ketamine administration, while 5 mg/kg/2h did not affect the levels. (27) Their findings emphasize that BDNF levels undergo time-dependent changes following ketamine administration that can be influenced by the dose and timing of assay, (26) something that might also explain the absence of effects in our study after dosing with 10 μg of LSD. Looking at the BDNF levels under the 20 μg dose condition suggests that the peak had yet to come. While the multiple assessment points in the present study were a strength, future studies might want to include extra assessment points beyond the 6 h postdrug period, even assessing the next day to understand the time-course of the effect.
    While microdosing implies taking repeated doses of a psychedelic for a prolonged time, the present study only assessed the acute effects of a single administration on BDNF levels. Future studies will have to assess the effects of repeated dosing on neuroplasticity to understand whether or not this practice is beneficial to neuroplasticity. Previous studies investigating the repeated administration of ketamine and classical psychedelics have provided mixed results. Preclinical studies, and studies in ketamine abusers, for example, have shown that long term administration decreases the BDNF production in animals and humans. (28,29) However, preclinical studies with repeated administration of high doses of serotonergic psychedelics demonstrated increased neuroplasticity. (27)
    Concerning the underlying pathway, previously it was shown that the structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways. (30) Ketamine is known to set off a signaling cascade by antagonizing NDMA receptors on presynaptic GABA neurons, resulting in an increased postsynaptic production of BDNF. The intermediate steps are increased presynaptic glutamate release and activation of mTOR pathways. (31−33) Ketamine and LSD might share a final common pathway when it comes to stimulation of BDNF. Future studies might include other proteins as well, to understand the neurobiological pathways underlying neuroplasticity and the potential (therapeutic) implications of these induced changes. Potential foci might be proteins such as cFos and Perk, implicated in synaptic plasticity and memory formation, (26) as ketamine is known to impact these.
    While the present study had a small final sample size due to the difficulty in collecting blood over the 6 h course the participants were in the lab, the strength was the within-subject set up which neutralized the variation in the placebo–LSD comparisons and the multiple measurements after administration. Besides emphasizing the need to sample BDNF beyond the LSD elimination stage, in addition to including behavioral and imaging measures, future studies could focus on similarities between underlying biological pathways of the well-studied ketamine and LSD, as these will contribute to understanding the scope of effects LSD might have, based on ketamine findings. This first evidence of neuroplasticity in humans after low doses of a psychedelic provides a foundation to explore and replicate this finding in patient populations, to understand the therapeutic value of it, if any exists.

    Materials and Methods

    ARTICLE SECTIONS
    Jump To
    Participants were 24 recreational psychedelic users who provided informed consent, fell within the inclusion criteria, (34) and passed medical screening including standard blood chemistry, hematology, and urinalysis before inclusion.
    Test days were scheduled with minimally 5 days in between. A test day started at 9:00 AM with a screen for the presence of drugs of abuse in urine and alcohol in the breath, as well as a urine pregnancy test for female participants. When tests were negative, a venous catheter was placed to draw blood. LSD (5, 10, and 20 μg LSD base) was dissolved in 96% ethanol; the placebo consisted of 1 mL of ethanol (96%) without LSD. LSD and placebo were administered orally at 10:00 AM. A dose of 5, 10, and 20 μg LSD base would be equivalent to respectively 6.2, 12.3, and 24.6 μg pure LSD tartrate (1:0.5 without any crystal water). Participants were allocated to unique treatment orders. Blood samples were taken at −0.5 h, +2 h, +4 h, and +6 h relative to drug administration using BD vacutainer heparin tubes spray-coated with lithium heparin. Samples were centrifuged, and plasma was transferred into a clean tube and frozen subsequently at −20 °C until analysis. BDNF determination was assessed using an ELISA kit (Biosensis Mature BDNF Rapid ELISA kit: human, mouse, rat; Thebarton, Australia). (18) Plasma samples were appropriately diluted (1:20), and detection of BDNF was carried out on a precoated mouse monoclonal anti-mature BDNF 96-well plate as described in the manufacturer’s protocol. The intra- and interassay coefficients of variation of this assay are below 10% (intra-assay CV 4.29%, interassay CV 7.14%). Samples were analyzed in duplicate, and mean values of respective measurements were calculated and used in statistical analyses. All measurements were done in a blinded fashion. LSD concentrations were determined using ultra-high-performance liquid chromatography/tandem mass spectrometry (UHPLC–MS/MS) as previously described. (35) A different extraction procedure reanalyzed samples with an LSD concentration below 5 pg/mL. In brief, aliquots of 150 μL of plasma were extracted with 450 μL of methanol. The samples were rigorously mixed and subsequently centrifuged. The supernatant was evaporated under a constant stream of nitrogen and resuspended in 200 μL of mobile phases A and B (10:90 v/v). An LLOQ of 2.5 pg/mL was reached by this extraction.
    This study is part of a more extensive study, including cognitive, psychological, and physiological parameters which are reported elsewhere. (34) The study adhered to the code of ethics on human experimentation, (36) was approved by the Medical Ethics Committee of the Academic Hospital of Maastricht and Maastricht University, and was registered in the Dutch Clinical Trial register (number: NTR7102 https://www.trialregister.nl/). A permit for obtaining, storing, and administering LSD was obtained from the Dutch Drug Enforcement Administration.

    Statistical Analysis

    ARTICLE SECTIONS
    Jump To
    Complete WS cases entered statistical analyses performed by the statistical program SPSS (version 25.0). Nonparametric Wilcoxon S-R tests for related samples (placebo–LSD dose) were conducted on BDNF AUC’s and BDNF plasma levels at −0.5 h, +2 h, +4 h, and +6 h after dose administration of 5, 10, and 20 μg of LSD. In order to understand at which time points BDNF levels were statistically different, separate Friedman tests per treatment condition were performed, and in the case of a main effect, followed by Dunn’s tests for pairwise comparisons including baseline (0 h) versus 2 h, 4 h, and 6 h, as well as 2 h–4 h and 4 h–6 h.
    In the case of statistically significant effects at alpha = 0.05, effect sizes and their 95% confidence intervals (95% CI) are given; to that end, (point-biserial) correlations are calculated for Wilcoxon tests where 0.10, 0.24, and 0.37 signify small, moderate, and large effect sizes; (37,38) in case of Friedman tests, Cramer’s V was calculated where 0.06, 0.17, and 0.29 signify small, moderate, and large effect sizes. (39) The alpha level was corrected for multiple comparisons with sequential Bonferroni in case of Dunn’s tests.

    Author Information

    ARTICLE SECTIONS
    Jump To
    • Corresponding Author
    • Authors
      • Nadia R. P. W. Hutten - Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht 6200 MD, The Netherlands
      • Natasha L. Mason - Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht 6200 MD, The Netherlands
      • Patrick C. Dolder - Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht 6200 MD, The Netherlands
      • Eef L. Theunissen - Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht 6200 MD, The Netherlands
      • Friederike Holze - Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel 4003, Switzerland
      • Matthias E. Liechti - Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel 4003, Switzerland;  Orcidhttp://orcid.org/0000-0002-1765-9659
      • Nimmy Varghese - Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel 4003, Switzerland
      • Anne Eckert - Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel 4003, Switzerland
      • Amanda Feilding - The Beckley Foundation, Beckley Park, Oxford OX3 9SY, United Kingdom
      • Johannes G. Ramaekers - Department of Neuropsychology & Psychopharmacology, Faculty of Psychology & Neuroscience, Maastricht University, Maastricht 6200 MD, The Netherlands
    • Author Contributions

      N.R.P.W.N., N.L.M., P.C.D., A.F., J.G.R., K.P.C.K. conceptualized the study and wrote the protocol. N.R.P.W.N., F.H., M.E.L., N.V., A.E., K.P.C.K. collected and/or analyzed the data. N.R.P.W.N. and K.P.C.K. wrote the manuscript. All authors contributed to versions leading up to the final manuscript.

    • Notes
      The authors declare no competing financial interest.

    Acknowledgments

    ARTICLE SECTIONS
    Jump To

    The authors thank the medical supervisor, Cees van Leeuwen, and the interns who worked on this project. A financial contribution was received from the Beckley Foundation.

    Abbreviations
    5-HT2A

    Serotonin 2A receptor

    BDNF

    Brain-derived neurotrophic factor

    CI

    Confidence interval

    ELISA

    Enzyme-linked immunosorbent assay

    i.p.

    Intraperitoneal

    IV

    Intraveneous

    LSD

    d-Lysergic acid diethylamide

    mPFC

    Medial prefrontal cortex

    mTOR

    Mammalian target of rapamycin

    NMDA

    N-Methyl-d-aspartate

    pERK

    Phosphorylation of extracellular signal-regulated kinase

    S-R

    Signed-rank

    WS

    Within subject

    References

    ARTICLE SECTIONS
    Jump To

    This article references 39 other publications.

    1. 1
      Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., and Olson, D. E. (2018) Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 23 (11), 3170– 3182,  DOI: 10.1016/j.celrep.2018.05.022
      [Crossref], [PubMed], [CAS], Google Scholar
    2. 2
      Catlow, B. J., Jalloh, A., and Sanchez-Ramos, J. (2016) Chapter 77 - Hippocampal Neurogenesis: Effects of Psychedelic Drugs, in Neuropathology of Drug Addictions and Substance Misuse (Preedy, V. R., Ed.), Academic Press, San Diego, CA, pp 821– 831.
      [Crossref], Google Scholar
    3. 3
      Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., and Riba, J. (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci. Rep. 7 (1), 5309,  DOI: 10.1038/s41598-017-05407-9
      [Crossref], [PubMed], [CAS], Google Scholar
    4. 4
      Farzin, D. and Mansouri, N. (2006) Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol. 16 (5), 324– 328,  DOI: 10.1016/j.euroneuro.2005.08.005
      [Crossref], [PubMed], [CAS], Google Scholar
    5. 5
      Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. (2010) Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. Journal of neural transmission 117 (10), 1131– 1137,  DOI: 10.1007/s00702-010-0451-2
      [Crossref], [PubMed], [CAS], Google Scholar
    6. 6
      Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., and Sanchez-Ramos, J. (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp. Brain Res. 228 (4), 481– 491,  DOI: 10.1007/s00221-013-3579-0
      [Crossref], [PubMed], [CAS], Google Scholar
    7. 7
      Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., and Caldas, E. D. (2020) Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats. Metab. Brain Dis. 35 (5), 739– 751,  DOI: 10.1007/s11011-020-00547-w
      [Crossref], [PubMed], [CAS], Google Scholar
    8. 8
      Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., and Frecska, E. (2016) The endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells. Front. Neurosci. 10, 423,  DOI: 10.3389/fnins.2016.00423
      [Crossref], [PubMed], [CAS], Google Scholar
    9. 9
      Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. d. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., and Rehen, S. K. (2017) Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci. Rep. 7 (1), 12863,  DOI: 10.1038/s41598-017-12779-5
      [Crossref], [PubMed], [CAS], Google Scholar
    10. 10
      Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., and Kuypers, K. P. C. (2019) Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Front. Psychiatry 10, 672,  DOI: 10.3389/fpsyt.2019.00672
      [Crossref], [PubMed], [CAS], Google Scholar
    11. 11
      Fadiman, J. (2011) The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys, Simon and Schuster.
      Google Scholar
    12. 12
      Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M, Nichols, C. D, Nichols, D. E, Pani, L., Soula, A., and Nutt, D. (2019) Microdosing Psychedelics: more questions than answers? An overview and suggestions for future research. J. Psychopharmacol. 33, 1039,  DOI: 10.1177/0269881119857204
      [Crossref], [PubMed], [CAS], Google Scholar
    13. 13
      Brunoni, A. R., Lopes, M., and Fregni, F. (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 11 (8), 1169– 80,  DOI: 10.1017/S1461145708009309
      [Crossref], [PubMed], [CAS], Google Scholar
    14. 14
      Price, R. B. and Duman, R. (2020) Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol. Psychiatry 25 (3), 530– 543,  DOI: 10.1038/s41380-019-0615-x
      [Crossref], [PubMed], [CAS], Google Scholar
    15. 15
      Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., and de Wit, H. (2020) Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity. Biological psychiatry. Cognitive neuroscience and neuroimaging 5 (4), 461– 467,  DOI: 10.1016/j.bpsc.2019.12.007
      [Crossref], [CAS], Google Scholar
    16. 16
      Allen, S. J. and Dawbarn, D. (2006) Clinical relevance of the neurotrophins and their receptors. Clin. Sci. 110 (2), 175– 91,  DOI: 10.1042/CS20050161
      [Crossref], [PubMed], [CAS], Google Scholar
    17. 17
      Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., Rockenstein, E., Chao, M. V., Koo, E. H., Geschwind, D., Masliah, E., Chiba, A. A., and Tuszynski, M. H. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat. Med. 15 (3), 331– 7,  DOI: 10.1038/nm.1912
      [Crossref], [PubMed], [CAS], Google Scholar
    18. 18
      Akimoto, H., Oshima, S., Sugiyama, T., Negishi, A., Nemoto, T., and Kobayashi, D. (2019) Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression. Behav. Brain Res. 359, 342– 352,  DOI: 10.1016/j.bbr.2018.11.017
      [Crossref], [PubMed], [CAS], Google Scholar
    19. 19
      Klein, A. B., Williamson, R., Santini, M. A., Clemmensen, C., Ettrup, A., Rios, M., Knudsen, G. M., and Aznar, S. (2011) Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 14 (3), 347– 353,  DOI: 10.1017/S1461145710000738
      [Crossref], [PubMed], [CAS], Google Scholar
    20. 20
      Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., and Duman, R. S. (2015) BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 18 (1), pyu033,  DOI: 10.1093/ijnp/pyu033
      [Crossref], Google Scholar
    21. 21
      de Almeida, R. N., Galvão, A. C. M., da Silva, F. S., Silva, E., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L. B., Lobão-Soares, B., and Galvão-Coelho, N. L. (2019) Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. Front. Psychol. 10, 1234,  DOI: 10.3389/fpsyg.2019.01234
      [Crossref], [PubMed], [CAS], Google Scholar
    22. 22
      Griffin, É. W., Bechara, R. G., Birch, A. M., and Kelly, Á. M. (2009) Exercise enhances hippocampal-dependent learning in the rat: Evidence for a BDNF-related mechanism. Hippocampus 19 (10), 973– 980,  DOI: 10.1002/hipo.20631
      [Crossref], [PubMed], [CAS], Google Scholar
    23. 23
      Hwang, J., Brothers, R. M., Castelli, D. M., Glowacki, E. M., Chen, Y. T., Salinas, M. M., Kim, J., Jung, Y., and Calvert, H. G. (2016) Acute high-intensity exercise-induced cognitive enhancement and brain-derived neurotrophic factor in young, healthy adults. Neurosci. Lett. 630, 247– 253,  DOI: 10.1016/j.neulet.2016.07.033
      [Crossref], [PubMed], [CAS], Google Scholar
    24. 24
      Duman, R. S. and Monteggia, L. M. (2006) A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59 (12), 1116– 1127,  DOI: 10.1016/j.biopsych.2006.02.013
      [Crossref], [PubMed], [CAS], Google Scholar
    25. 25
      Woelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., and Walter, M. (2019) Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry 1– 15,  DOI: 10.1080/15622975.2019.1679391
      [Crossref], [CAS], Google Scholar
    26. 26
      Zhang, M., Radford, K. D., Driscoll, M., Purnomo, S., Kim, J., and Choi, K. H. (2019) Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats. IBRO Reports 6, 87– 94,  DOI: 10.1016/j.ibror.2019.01.006
      [Crossref], [PubMed], [CAS], Google Scholar
    27. 27
      Radford, C. K. D., Park, T. Y., Osborne-Smith, L., and Choi, K. H. (2018) Effects of Subanesthetic Intravenous Ketamine Infusion on Corticosterone and Brain-Derived Neurotrophic Factor in the Plasma of Male Sprague-Dawley Rats. AANA J. 86 (5), 393– 400
      [PubMed], [CAS], Google Scholar
    28. 28
      Fraga, D. B., Réus, G. Z., Abelaira, H. M., De Luca, R. D., Canever, L., Pfaffenseller, B., Colpo, G. D., Kapczinski, F., Quevedo, J., and Zugno, A. I. (2013) Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration. Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999) 35 (3), 262– 6,  DOI: 10.1590/1516-4446-2012-0858
      [Crossref], [PubMed], [CAS], Google Scholar
    29. 29
      Ke, X., Ding, Y., Xu, K., He, H., Zhang, M., Wang, D., Deng, X., Zhang, X., Zhou, C., Liu, Y., Ning, Y., and Fan, N. (2014) Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug Alcohol Depend. 142, 290– 4,  DOI: 10.1016/j.drugalcdep.2014.06.043
      [Crossref], [PubMed], [CAS], Google Scholar
    30. 30
      Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R. (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep. 23 (11), 3170– 3182,  DOI: 10.1016/j.celrep.2018.05.022
      [Crossref], [PubMed], [CAS], Google Scholar
    31. 31
      Moghaddam, B., Adams, B., Verma, A., and Daly, D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (8), 2921– 7,  DOI: 10.1523/JNEUROSCI.17-08-02921.1997
      [Crossref], [PubMed], [CAS], Google Scholar
    32. 32
      Browne, C. A. and Lucki, I. (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front. Pharmacol. 4, 161– 161,  DOI: 10.3389/fphar.2013.00161
      [Crossref], [PubMed], [CAS], Google Scholar
    33. 33
      Duman, R. S., Li, N., Liu, R.-J., Duric, V., and Aghajanian, G. (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62 (1), 35– 41,  DOI: 10.1016/j.neuropharm.2011.08.044
      [Crossref], [PubMed], [CAS], Google Scholar
    34. 34
      Ramaekers, J. G., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., and Kuypers, K. P. (2020) A low dose of lysergic acid diethylamide (LSD) decreases pain perception in healthy volunteers. J. Psychopharmacol. DOI: 10.1177/0269881120940937
      [Crossref], Google Scholar
    35. 35
      Holze, F., Duthaler, U., Vizeli, P., Müller, F., Borgwardt, S., and Liechti, M. E. (2019) Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br. J. Clin. Pharmacol. 85, 1474,  DOI: 10.1111/bcp.13918
      [Crossref], [PubMed], [CAS], Google Scholar
    36. 36
      World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310 (20), 2191– 2194,  DOI: 10.1001/jama.2013.281053
      [Crossref], [PubMed], Google Scholar
    37. 37
      Ivarsson, A., Andersen, M. B., Johnson, U., and Lindwall, M. (2013) To adjust or not adjust: Nonparametric effect sizes, confidence intervals, and real-world meaning. Psychology of Sport and Exercise 14 (1), 97– 102,  DOI: 10.1016/j.psychsport.2012.07.007
      [Crossref], Google Scholar
    38. 38
      Kornbrot, D. (2014) Point Biserial Correlation, in Wiley StatsRef: Statistics Reference Online, Wiley. https://onlinelibrary.wiley.com/doi/10.1002/9781118445112.stat06227.
      Google Scholar
    39. 39
      Kim, H.-Y. (2017) Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod 42 (2), 152– 155,  DOI: 10.5395/rde.2017.42.2.152
      [Crossref], [PubMed], [CAS], Google Scholar

    Cited By

    This article is cited by 16 publications.

    1. David E. Olson. The Promise of Psychedelic Science. ACS Pharmacology & Translational Science 2021, 4 (2) , 413-415. https://doi.org/10.1021/acsptsci.1c00071
    2. L. S. Kaertner, M. B. Steinborn, H. Kettner, M. J. Spriggs, L. Roseman, T. Buchborn, M. Balaet, C. Timmermann, D. Erritzoe, R. L. Carhart-Harris. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Scientific Reports 2021, 11 (1) https://doi.org/10.1038/s41598-021-81446-7
    3. Robin J. Murphy, Rachael L. Sumner, William Evans, David Menkes, Ingo Lambrecht, Rhys Ponton, Frederick Sundram, Nicholas Hoeh, Sanya Ram, Lisa Reynolds, Suresh Muthukumaraswamy. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. Trials 2021, 22 (1) https://doi.org/10.1186/s13063-021-05243-3
    4. Anna M. Becker, Friederike Holze, Tanja Grandinetti, Aaron Klaiber, Vanja E. Toedtli, Karolina E. Kolaczynska, Urs Duthaler, Nimmy Varghese, Anne Eckert, Edna Grünblatt, Matthias E. Liechti. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology & Therapeutics 2021, 78 https://doi.org/10.1002/cpt.2487
    5. Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler. Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 2021, 68 https://doi.org/10.1007/s40429-021-00401-8
    6. Lily R. Aleksandrova, Anthony G. Phillips. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences 2021, 42 (11) , 929-942. https://doi.org/10.1016/j.tips.2021.08.003
    7. Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Frontiers in Psychiatry 2021, 12 https://doi.org/10.3389/fpsyt.2021.724606
    8. Lisa M. Reynolds, Amelia Akroyd, Frederick Sundram, Aideen Stack, Suresh Muthukumaraswamy, William J. Evans. Cancer Healthcare Workers’ Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation. International Journal of Environmental Research and Public Health 2021, 18 (15) , 8160. https://doi.org/10.3390/ijerph18158160
    9. Friederike Holze, Isidora Avedisian, Nimmy Varghese, Anne Eckert, Matthias E. Liechti. Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Frontiers in Pharmacology 2021, 12 https://doi.org/10.3389/fphar.2021.711255
    10. Hewa Artin, Sidney Zisook, Dhakshin Ramanathan. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World Journal of Psychiatry 2021, 11 (6) , 201-214. https://doi.org/10.5498/wjp.v11.i6.201
    11. Matthew I. Banks, Zarmeen Zahid, Nathan T. Jones, Ziyad W. Sultan, Cody J. Wenthur, . Catalysts for change: the cellular neurobiology of psychedelics. Molecular Biology of the Cell 2021, 32 (12) , 1135-1144. https://doi.org/10.1091/mbc.E20-05-0340
    12. Balázs Szigeti, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J Nutt, Robin L Carhart-Harris, David Erritzoe. Self-blinding citizen science to explore psychedelic microdosing. eLife 2021, 10 https://doi.org/10.7554/eLife.62878
    13. Paul Tullis. How ecstasy and psilocybin are shaking up psychiatry. Nature 2021, 589 (7843) , 506-509. https://doi.org/10.1038/d41586-021-00187-9
    14. Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi, . Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews 2021, 73 (1) , 202-277. https://doi.org/10.1124/pharmrev.120.000056
    15. Nakul Ravi Raval, Annette Johansen, Lene Lundgaard Donovan, Nídia Fernandez Ros, Brice Ozenne, Hanne Demant Hansen, Gitte Moos Knudsen. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. International Journal of Molecular Sciences 2021, 22 (2) , 835. https://doi.org/10.3390/ijms22020835
    16. Nadia R.P.W. Hutten, Natasha L. Mason, Patrick C. Dolder, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding, Johannes G. Ramaekers, Kim P.C. Kuypers. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology 2020, 41 , 81-91. https://doi.org/10.1016/j.euroneuro.2020.10.002

    • Abstract

      Figure 1

      Figure 1. Total mean AUC (SEM) of BDNF (A) and of LSD (B) plasma levels for complete WS LSD dose-placebo cases. N(5 μg LSD) = 10; N(10 μg LSD) = 9; N(20 μg LSD) = 8. *, statistical significance at p ≤ 0.05.

      Figure 2

      Figure 2. Mean (SEM) BDNF plasma levels for each LSD dose with the corresponding WS placebo condition per time of testing (A–C) and corresponding mean (SEM) LSD plasma levels (D–F). *, statistical significance at p ≤ 0.05 in A–C; no statistical tests were performed over data in D–F.

    back